Licensing Agreement

Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China

Innovent

Oncology

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer

Innovent Biologics, Inc.

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt®

Innovent